Home
clear space
Press Releases Line Publications Line Presentations Line Posters Line

Tolero Pharmaceuticals Presents Preclinical Data on CDK9 Inhibitor Alvocidib and its Prodrug, TP-1287, at AACR 2017


Preclinical Data supports the potential role of CDK9-mediated targeting of MCL-1 in treatment of therapy-resistant cancers
SALT LAKE CITY, UT --Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, presented preclinical data on alvocidib, an investigational inhibitor of cyclin-dependent kinase 9 (CDK9), in Phase II development for relapsed/refractory acute myeloid leukemia (AML) and its prodrug, TP-1287..... (More) Line

Sumitomo Dainippon Pharma Completes Acquisition of Tolero Pharmaceuticals, Inc. (US Biotechnology Company)


January 26, 2017 - Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan; President: Masayo Tada; Securities Code: 4506, First Section of TSE, "Sumitomo Dainippon Pharma") announced today that it has completed the acquisition of Tolero Pharmaceuticals, Inc. (Head office: Lehi, UT, U.S., CEO: David J. Bearss., "Tolero") as of January 25, 2017 (U.S. Pacific Standard Time).... (More) Line

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)


December 21, 2016 - Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka, Japan; President: Masayo Tada; Securities Code: 4506, First Section of TSE, "Sumitomo Dainippon Pharma") announced today that the company and Tolero Pharmaceuticals, Inc. (Head office: Lehi, UT, U.S., CEO: David J. Bearss., "Tolero") have reached an agreement on December 21, 2016 on the acquisition of Tolero through U.S. Holding company wholly owned by Sumitomo Dainippon Pharma.... (More) Line

Tolero Pharmaceuticals to Present Progress of Leukemia and Anemia Programs at the 58th ASH Annual Meeting and Exposition


SALT LAKE CITY, UT - November 15, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for oncology and hematological diseases, announced today that it will present one oral and one poster presentation at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, December 3 through 6, 2016. The presentations include nonclinical results that further support... (More) Line

Tolero Pharmaceuticals to Present at the International Conference on Leukemia and Hematologic Oncology in Rome, Italy


SALT LAKE CITY, UT - October 11, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for oncology and hematological diseases, announced today that David J. Bearss, Ph.D., Chief Executive Officer, is scheduled to present the keynote address at the International Conference on Leukemia and Hematologic Oncology, which is being held from October 17-18, 2016 in Rome, Italy... (More) Line

Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Drug Combination Strategies Due to the Targeting of MCL-1


Poster presented at the 21st EHA Congress
SALT LAKE CITY, UT - June 13, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for oncology and hematologic diseases, today announced that its lead clinical candidate, alvocidib, demonstrates high synergistic activity with the B-cell lymphoma-2 (BCL-2) inhibitor, venetoclax (ABT-199) in nonclinical models of... (More) Line

Tolero Pharmaceuticals to Present Updates on Clinical and Preclinical Programs at the 2016 EHA Congress


SALT LAKE CITY, UT - June 6, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present two poster presentations at The 21st European Hematology Association (EHA) Congress in Copenhagen, Denmark, June 9 through 12, 2016... (More) Line

Tolero Pharmaceuticals to Present at the Jefferies 2016 Global Healthcare Conference


SALT LAKE CITY, UT - June 6, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious hematological diseases, announced today that it will present at the Jefferies 2016 Global Healthcare Conference taking place June 7-10, 2016 in New York City. David J. Bearss, Ph.D., Chief Executive Officer, is scheduled to present... (More) Line

Tolero Pharmaceuticals Presents Nonclinical Data Demonstrating Alvocidib Provides Multiple Drug Combination Strategies Due to the Targeting of MCL-1


Poster presented at the AACR Annual Meeting 2016
SALT LAKE CITY, UT - April 20, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for oncology and hematologic diseases, today announced that its lead clinical candidate, alvocidib, demonstrated profound synergistic activity with agents rendered less active due to myeloid cell leukemia 1 (MCL-1) dependence. The data were presented in a poster entitled "Targeting MCL-1 expression... (More) Line

Tolero Pharmaceuticals Presents Data Demonstrating AXL Inhibition Leads to a Reversal of a Mesenchymal Phenotype Sensitizing Cancer Cells to Targeted Agents and Immuno-Oncology Therapies


Poster presented at the AACR Annual Meeting 2016
SALT LAKE CITY, UT - April 18, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for oncology and hematologic diseases, today announced the presentation of positive preclinical data on TP-0903, an AXL kinase inhibitor. In the data presented, Tolero demonstrated that the AXL inhibitor, TP-0903, sensitized cancer cells to various immuno-oncology agents including an immune checkpoint inhibitor... (More) Line

Tolero Pharmaceuticals to Present Updates on Clinical and Preclinical Programs at the AACR Annual Meeting 2016


SALT LAKE CITY, UT - April 12, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana, April 16 through 20, 2016......(More) Line

Tolero Pharmaceuticals to Present at the 13th Annual BIO Asia International Conference


SALT LAKE CITY, UT - March 8, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious hematological diseases announced today that it will present at the 13th Annual BIO Asia International Conference taking place March 15-16, 2016 at the Grand Hyatt, Tokyo, Japan. David J. Bearss, Ph.D., Chief Executive Officer, is scheduled to present at 10:00 AM (JST) on Wednesday, March 16, 2016.....(More) Line

Tolero Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference


SALT LAKE CITY, UT - January 4, 2016 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious hematological diseases, today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference taking place January 11-14, 2016 at the Westin St. Francis Hotel in San Francisco, California. David J. Bearss, Chief Executive Officer, is scheduled to present at 10:30 AM (PST) on Wednesday, January 13, 2016....(More) Line

Tolero Pharmaceuticals Presents Positive Preclinical Data on Hepcidin Inhibition for the Treatment of Anemia Associated with Chronic Disease

Data Presented in Oral Presentation at the 57th ASH Annual Meeting and Exposition

SALT LAKE CITY, UT - December 7, 2015 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious hematological diseases, today announced that it presented positive preclinical data on its hepcidin lowering agent, TP-0184, in an oral presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida....(More) Line

Tolero Pharmaceuticals Presents Preclinical Data Demonstrating Synergistic Activity with a Combination of Alvocidib and Azacytidine

Data Presented in Oral Presentation at the 57th ASH Annual Meeting and Exposition

SALT LAKE CITY, UT - December 7, 2015 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious hematological diseases, today announced that its lead clinical candidate, alvocidib, demonstrated profound synergistic activity with 5-azacytidine in nonclinical models of hematological malignancies. These data were presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida....(More) Line

Tolero Pharmaceuticals Presents Data Demonstrating Inhibition of AXL Kinase in Cancer Cells Restores Drug Sensitivity Through a Mechanism Involving Retinoic Acid Signaling

Data Presented in Oral Presentation at the 57th ASH Annual Meeting and Exposition

SALT LAKE CITY, UT - December 7, 2015 - Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced the presentation of positive preclinical data on TP-0903, an AXL kinase inhibitor, in a poster at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida....(More) Line

Tolero Pharmaceuticals Announces Mechanistic Data Describing the Activity of Alvocidib within a Time-sequential Regimen

Data Presented in Oral Presentation at the 57th ASH Annual Meeting and Exposition

SALT LAKE CITY, UT - December 8, 2015 - Tolero Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing treatments for serious hematological diseases, today announced that data for its lead clinical candidate, alvocidib, was presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida....(More) Line

Tolero Pharmaceuticals Presents Positive Clinical and Preclinical Data on Programs in Leukemia and Anemia at the 57th ASH Annual Meeting and Exposition


SALT LAKE CITY, UT - November 12, 2015 - Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present one oral and three poster presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida, December 5 through 8, 2015....(More) Line

Tolero Pharmaceuticals Executes Exclusive License with Eutropics for Novel Companion Diagnostic Platform PraediCareDx™


SALT LAKE CITY, UT - November 9, 2015 - Tolero Pharmaceuticals, Inc., a late-stage pharmaceutical company developing treatments for serious hematological diseases, today announced that it has entered into an exclusive license to use Eutropics PraediCare Dx™ platform in the clinical development of alvocidib. Preliminary studies have suggested that PraediCareDx can be used to identify acute myeloid leukemia (AML) patients with a high likelihood of responding to alvocidib....(More) Line

Tolero Pharmaceuticals Presents Results Providing Strong Rationale for Combining Alvocidib with a Bromodomain Protein Inhibitor for the Treatment of Multiple Tumor Types


SALT LAKE CITY, UT - November 9, 2015 - Tolero Pharmaceuticals, Inc., today announced the presentation of nonclinical data demonstrating synergy between the CDK9 inhibitor, alvocidib, and a number of bromo and extra terminal (BET) protein inhibitors in multiple tumor models at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting in Boston, MA....(More)
clear space